Literature DB >> 16714674

Flare response in 18F-fluoride ion PET bone scanning.

Andrew A Wade1, James A Scott, Irene Kuter, Alan J Fischman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16714674     DOI： 10.2214/AJR.05.0225

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN： 0361-803X            Impact factor:   3.959


× No keyword cloud information.
  22 in total

1.  Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer.

Authors:  Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04       Impact factor: 9.236

Review 2.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

3.  Giving oligometastases the best shot using stereotactic body radiosurgery with image guidance. How far is the cat out of the bag?

Authors:  Johnny Yap
Journal:  J Gastrointest Oncol       Date:  2010-09

4.  Single-fraction image-guided extracranial radiosurgery for recurrent and metastatic abdominal and pelvic cancers: short-term local control, metabolic response, and toxicity.

Authors:  Charles L Perkins; Bassel El-Reyes; Edmund Simon; David Kooby; William Torres; John S Kauh; Charles A Staley; Jerome C Landry
Journal:  J Gastrointest Oncol       Date:  2010-09

5.  18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin).

Authors:  Gary Cook; Chris Parker; Sue Chua; Bernadette Johnson; Anne-Kirsti Aksnes; Val J Lewington
Journal:  EJNMMI Res       Date:  2011-06-07       Impact factor: 3.138

6.  Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases.

Authors:  Robert K Doot; Mark Muzi; Lanell M Peterson; Erin K Schubert; Julie R Gralow; Jennifer M Specht; David A Mankoff
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

7.  Sodium 18F-fluoride PET/CT of bone, joint, and other disorders.

Authors:  Hossein Jadvar; Bhushan Desai; Peter S Conti
Journal:  Semin Nucl Med       Date:  2015-01       Impact factor: 4.446

8.  Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.

Authors:  Hossein Jadvar; Bhushan Desai; Lingyun Ji; Peter S Conti; Tanya B Dorff; Susan G Groshen; Mitchell E Gross; Jacek K Pinski; David I Quinn
Journal:  Clin Nucl Med       Date:  2012-07       Impact factor: 7.794

Review 9.  Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.

Authors:  Laura Evangelista; Francesco Bertoldo; Francesco Boccardo; Giario Conti; Ilario Menchi; Francesco Mungai; Umberto Ricardi; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-09       Impact factor: 9.236

10.  A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.

Authors:  Dana Yip; Maithao N Le; Joseph L-K Chan; Jonathan H Lee; Janice A Mehnert; Anthony Yudd; Jeffery Kempf; Weichung J Shih; Suzie Chen; James S Goydos
Journal:  Clin Cancer Res       Date:  2009-05-19       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.